Celgene Reports Improvement in Patients with Moderate-to-Severe Plaque Psoriasis with OTEZLA in P-III ESTEEM trial
Shots:
- Results: ESTEEM 1- 2: NAPSI@32wk (31.3% vs 15.5)- DLQI @16wks. (28.7% vs 8.1%); UNVEIL: NAPSI@32wks. (36.2% vs 37.2%)- DLQI@16wks. (23.7% vs 10.6%)
- Though- Post-hoc analysis revealed that OTEZLA was not able to achieve PASi75@32/52wks
- A 5-year extension study of ESTEEM 1 and 2 is ongoing. OTEZLA (apremilast) (PDE4i) marketed as 30 mg PO indicated for the treatment of patients with moderate-to-severe plaque psoriasis
- Another study UNVEIL is assessing safety and efficacy of OTEZLA in patients with ratio (2:1) administering either 30 mg bid or PBO with moderate plaque psoriasis
- ESTEEM (1(PSAI 75)- 2(PSAI 50)) involves assessing of OTEZLA with changes in scalp and nail psoriasis & QoL in patients with moderate to severe plaque & nail psoriasis in ratio (2:1) administering either 30 mg bid or PBO for 16 wks. after an initial five-day titration period
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
